Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	24.06B
Revenue (ttm)	4.91B
Net Income (ttm)	1.09B
Shares Out	2.23B
EPS (ttm)	0.49
PE Ratio	22.13
Forward PE	15.53
Dividend	0.27 (2.50%)
Ex-Dividend Date	Jun 10, 2025

Volume	14,042,870
Average Volume	15,616,516
Open	10.89
Previous Close	10.95
Day's Range	10.75 - 10.89
52-Week Range	10.75 - 16.58
Beta	0.16
RSI	26.78
Earnings Date	Oct 21, 2025

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; urso...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,184
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2024, SHE:301301's revenue was 5.76 billion, an increase of 19.38% compared to the previous year's 4.82 billion. Earnings were 1.40 billion, an increase of 48.88%.